Osteoporosis Risk Assessment
Please ensure that the Discussion includes more than 400 words with scholarly articles, and the plagiarism level must remain below 20%.
Answer the following items using your own words. Be objective and concise while being professional.
1. During a case presentation at your clinic, you review four women with predisposing factors for osteoporosis. Which patient is least likely to be at risk for osteoporosis?
A. Nehineza, who has more weight African American female with a family history of uterine cancer
B. Cristina, a Hispanic woman living a sedentary life
C. Park-Gim-Ka, an underweight Asian woman with a history of tobacco use
D. Skylar, a Caucasian woman experiencing early onset of menopause.
2. Densitometry results are given as T-scores. Which values would be considered osteopenia?
3. After prompt analysis of your patient, you decide to institute treatment for osteoporosis. Which class of medication is considered the first-line treatment? Are there any considerations to be made prior to starting therapy? Which recommendations would you provide to the patient regarding this treatment?
APA
Check out our Essay writing services
Osteoporosis Risk Assessment
Identifying Osteoporosis Risk and Interpreting Densitometry
Furthermore, African American women statistically have greater bone density than other ethnic groups, reducing their risk of developing osteoporosis (NIH Osteoporosis and Related Bone Diseases, 2021).
Densitometry results are reported as T-scores, which compare the patient’s bone mineral density (BMD) to that of a healthy young adult. A T-score between −1.0 and −2.5 indicates osteopenia, a condition in which bone density is lower than normal but not low enough to be classified as osteoporosis (Wright et al., 2022). A score of −2.5 or lower confirms a diagnosis of osteoporosis.
Treatment of Osteoporosis and Patient Counseling
The first-line treatment for osteoporosis is typically bisphosphonates, such as alendronate or risedronate. These medications work by inhibiting bone resorption and increasing bone mass (Eastell et al., 2016). Before initiating therapy, it is essential to evaluate the patient’s renal function, as bisphosphonates can cause renal toxicity……..
